DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies f

New Strong Sell Stocks for August 10th

02:01pm, Monday, 10'th Aug 2020
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi
Analysts predict that Aerie Pharmaceuticals Inc (NASDAQ:AERI) will post ($0.79) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided e
Aerie Pharmaceuticals Inc (NASDAQ:AERI) saw a large drop in short interest in July. As of July 15th, there was short interest totalling 8,050,000 shares, a drop of 10.6% from the June 30th total of 9,
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi
Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celsion advances Phase II advanced ovarian cancer trial. Zentalis inks clinical collaboration with Eli Lilly.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi
Aerie Pharmaceuticals (NASDAQ:AERI) and Seattle Genetics (NASDAQ:SGEN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market
Parametric Portfolio Associates LLC reduced its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 64.6% during the first quarter, according to the company in its most recent 13F filing wit
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE